Published in JAMA Ophthalmol on June 01, 2013
Topical IL-1-Ra for Treatment of Posterior Blepharitis | NCT00681109
Treating inflammation by blocking interleukin-1 in humans. Semin Immunol (2013) 1.75
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology (Oxford) (2015) 1.01
A randomized controlled trial of omega-3 fatty acids in dry eye syndrome. Int J Ophthalmol (2013) 1.00
Managing Sjögren's Syndrome and non-Sjögren Syndrome dry eye with anti-inflammatory therapy. Clin Ophthalmol (2014) 0.89
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm (2015) 0.89
Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis (2013) 0.85
Design of a superior cytokine antagonist for topical ophthalmic use. Proc Natl Acad Sci U S A (2013) 0.84
Corneal sensitivity following lacrimal gland excision in the rat. Invest Ophthalmol Vis Sci (2015) 0.81
Bilateral corneal ulceration in ocular graft-versus-host disease. Clin Ophthalmol (2013) 0.81
Targeting Imbalance between IL-1β and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas. Am J Pathol (2016) 0.79
Understanding Neuropathic Corneal Pain-Gaps and Current Therapeutic Approaches. Semin Ophthalmol (2016) 0.79
Establishing PAX6 as a biomarker to detect early loss of ocular phenotype in human patients with Sjögren's syndrome. Invest Ophthalmol Vis Sci (2014) 0.79
Dry Eye Signs and Symptoms Persist During Systemic Neutralization of IL-1β by Canakinumab or IL-17A by Secukinumab. Cornea (2015) 0.78
Aberrant interleukin-1 signalling does not increase susceptibility of mice to NOD2-dependent uveitis. Clin Experiment Ophthalmol (2014) 0.77
Immunomodulation on the ocular surface: a review. Cent Eur J Immunol (2016) 0.76
Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells? Invest Ophthalmol Vis Sci (2016) 0.76
High Frequency of Latent Conjunctival C. trachomatis, M. hominis, and U. urealyticum Infections in Young Adults with Dry Eye Disease. J Ophthalmol (2014) 0.76
Evaluation of patients with dry eye disease for conjunctival Chlamydia trachomatis and Ureaplasma urealyticum. Int J Ophthalmol (2016) 0.75
Anti-inflammatory effects of hinokitiol on human corneal epithelial cells: an in vitro study. Eye (Lond) (2015) 0.75
The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf (2007) 11.76
Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol (2000) 6.55
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood (2011) 5.61
Prevalence of dry eye syndrome among US women. Am J Ophthalmol (2003) 4.46
Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol (2007) 3.96
Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease. Invest Ophthalmol Vis Sci (2001) 3.72
Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res (1999) 2.75
Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology (2000) 2.74
Utility assessment among patients with dry eye disease. Ophthalmology (2003) 2.71
Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies. Arch Ophthalmol (2009) 2.65
IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol (2009) 2.65
Corneal epithelial wound healing. Exp Biol Med (Maywood) (2001) 2.45
The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci (2011) 2.28
Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp Eye Res (2006) 2.27
Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol (2012) 2.23
Impaired functional visual acuity of dry eye patients. Am J Ophthalmol (2002) 1.94
JNK and ERK MAP kinases mediate induction of IL-1beta, TNF-alpha and IL-8 following hyperosmolar stress in human limbal epithelial cells. Exp Eye Res (2005) 1.76
Neural basis of sensation in intact and injured corneas. Exp Eye Res (2004) 1.75
Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome. Invest Ophthalmol Vis Sci (2009) 1.75
Meibomian gland dysfunction: a clinical scheme for description, diagnosis, classification, and grading. Ocul Surf (2003) 1.73
Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. J Rheumatol (2008) 1.43
The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea (2011) 1.32
Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci (2010) 1.29
Characterization of effector T cells in dry eye disease. Invest Ophthalmol Vis Sci (2009) 1.21
Evaluation of topical cyclosporine for the treatment of dry eye disease. Arch Ophthalmol (2008) 1.21
Doxycycline inhibition of interleukin-1 in the corneal epithelium. Invest Ophthalmol Vis Sci (2000) 1.19
Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol (2012) 1.18
Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol (2009) 1.16
Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology (2005) 1.15
Wavefront analysis of higher order aberrations in dry eye patients. J Refract Surg (2004) 1.11
Expression of collagenolytic/gelatinolytic metalloproteinases by normal cornea. Invest Ophthalmol Vis Sci (1990) 1.06
Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci (2009) 1.04
Detection of mRNA for the cytokines, interleukin-1 alpha and interleukin-8, in corneas from patients with pseudophakic bullous keratopathy. Invest Ophthalmol Vis Sci (1995) 0.99
Local suppression of IL-1 by receptor antagonist in the rat model of corneal alkali injury. Exp Eye Res (2003) 0.98
Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain (2010) 0.92
Anion binding and controlled aggregation of human interleukin-1 receptor antagonist. Biochemistry (2005) 0.91
Binding sites for human interleukin 1 alpha, gamma interferon and tumor necrosis factor on cultured fibroblasts of normal cornea and keratoconus. Curr Eye Res (1991) 0.90
Estimating the prevalence of dry eye among Indian patients attending a tertiary ophthalmology clinic. Ann Trop Med Parasitol (2010) 0.89
Unpreserved carboxymethylcellulose artificial tears evaluated in patients with keratoconjunctivitis sicca. Cornea (1992) 0.89
A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. Self Nonself (2011) 0.87
Prevention of allergic eye disease by treatment with IL-1 receptor antagonist. Invest Ophthalmol Vis Sci (1999) 0.87
Interleukin-1 receptor antagonist therapy and induction of anterior chamber-associated immune deviation-type tolerance after corneal transplantation. Invest Ophthalmol Vis Sci (2000) 0.85
Focus on molecules: interleukin-1: a master regulator of the corneal response to injury. Exp Eye Res (2009) 0.85